Literature DB >> 30398106

Cancer Immunoinformatics: A Promising Era in the Development of Peptide Vaccines for Human Papillomavirus-induced Cervical Cancer.

Satyavani Kaliamurthi1,2, Gurudeeban Selvaraj1,2, Muhammad Junaid3, Abbas Khan3, Keren Gu1,2, Dong-Qing Wei1,3.   

Abstract

Cancer immunoinformatics have led to new directions towards vaccine design from predicted potential epitope candidates, which are able to stimulate the correct cellular or humoral immune responses. They were employed to accomplish an advanced vaccine design through reverse vaccinology by replacing the whole organisms. In this review, computational tools play an essential role in evaluating multiple proteomes to identify and select the potential targeted epitopes or combinations of distinct epitopes, so that candidates may afford a rationale design competent for obtaining suitable cytotoxic T lymphocytes (CTL) or B cell-mediated immune responses. This review is a complete collection of the most beneficial online and user-friendly immunological tools, servers, and databases for the design and development of the peptide vaccine. The mechanism of major histocompatability (MHC)-restricted peptide presentation and how these tools support the vaccine development are also presented. The human papillomavirus (HPV) is taken as a model microbial strain for peptide vaccine design and its sensitization against HPV-induced cervical cancer is discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Cervical cancer; consensus approach; epitopes; human papillomavirus; major histocompatibility complex; vaccine.

Mesh:

Substances:

Year:  2018        PMID: 30398106     DOI: 10.2174/1381612824666181106094133

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Experimental Study of Potential CD8+ Trivalent Synthetic Peptides for Liver Cancer Vaccine Development Using Sprague Dawley Rat Models.

Authors:  Sidra Zafar; Baogang Bai; Jinlei Guo; Syed Aun Muhammad; Syeda Tahira Qousain Naqvi; Muhammad Nauman Shabbir; Imran Imran; Rehan Sadiq Shaikh; Amjad Ali
Journal:  Biomed Res Int       Date:  2022-05-31       Impact factor: 3.246

2.  EpiBuilder: A Tool for Assembling, Searching, and Classifying B-Cell Epitopes.

Authors:  Renato Simões Moreira; Vilmar Benetti Filho; Nathália Anderson Calomeno; Glauber Wagner; Luiz Claudio Miletti
Journal:  Bioinform Biol Insights       Date:  2022-05-11

3.  Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology.

Authors:  Satyavani Kaliamurthi; Gurudeeban Selvaraj; Sathishkumar Chinnasamy; Qiankun Wang; Asma Sindhoo Nangraj; William Cs Cho; Keren Gu; Dong-Qing Wei
Journal:  Viruses       Date:  2019-01-15       Impact factor: 5.048

4.  In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.

Authors:  Ali Namvar; Azam Bolhassani; Gholamreza Javadi; Zahra Noormohammadi
Journal:  Sci Rep       Date:  2019-10-23       Impact factor: 4.379

Review 5.  Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances.

Authors:  Jiahui Zhang; Jingyi Fan; Mariusz Skwarczynski; Rachel J Stephenson; Istvan Toth; Waleed M Hussein
Journal:  Int J Nanomedicine       Date:  2022-02-25

6.  In silico Analysis, Molecular Docking, Molecular Dynamic, Cloning, Expression and Purification of Chimeric Protein in Colorectal Cancer Treatment.

Authors:  Hassan Dana; Ghanbar Mahmoodi Chalbatani; Elahe Gharagouzloo; Seyed Rouhollah Miri; Fereidoon Memari; Reza Rasoolzadeh; Mohammad Reza Zinatizadeh; Peyman Kheirandish Zarandi; Vahid Marmari
Journal:  Drug Des Devel Ther       Date:  2020-01-23       Impact factor: 4.162

7.  In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.

Authors:  Matin Kayyal; Azam Bolhassani; Zahra Noormohammadi; Majid Sadeghizadeh
Journal:  Mol Biotechnol       Date:  2021-07-25       Impact factor: 2.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.